AG
CSTL icon

Algert Global’s Castle Biosciences CSTL Stock Holding History

Algert Global’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$854K Buy
34,778
+15,800
+83% +$517K 0.01% 893
2025
Q4 		$738K Sell
18,978
-38,917
-67% -$1.25M 0.01% 896
2025
Q3 		$1.32M Sell
57,895
-127,286
-69% -$2.59M 0.02% 787
2025
Q2 		$3.78M Buy
185,181
+40,870
+28% +$757K 0.08% 423
2025
Q1 		$2.89M Sell
144,311
-5,180
-3% -$128K 0.07% 479
2024
Q4 		$3.98M Buy
149,491
+15,170
+11% +$462K 0.09% 356
2024
Q3 		$3.83M Buy
134,321
+599
+0.4% +$15.2K 0.1% 337
2024
Q2 		$2.91M Sell
133,722
-11,685
-8% -$260K 0.1% 342
2024
Q1 		$3.22M Buy
145,407
+16,297
+13% +$355K 0.13% 272
2023
Q4 		$2.79M Buy
129,110
+61,898
+92% +$1.09M 0.11% 307
2023
Q3 		$1.14M Sell
67,212
-21,860
-25% -$382K 0.05% 541
2023
Q2 		$1.22M Buy
89,072
+19,690
+28% +$399K 0.05% 588
2023
Q1 		$1.58M Buy
69,382
+530
+0.8% +$12.9K 0.07% 427
2022
Q4 		$1.62M Buy
68,852
+18,920
+38% +$439K 0.09% 371
2022
Q3 		$1.3M Buy
+49,932
New +$1.4M 0.08% 434

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Algert Global's CSTL Position: Q1 2026 in Review

Algert Global increased its Castle Biosciences (CSTL) stake by 83% in Q1 2026, buying an estimated $517K and bringing the position to 34,778 shares worth $854K. The position accounts for 0.01% of the portfolio, ranked #893.

Algert Global first reported a position in CSTL in Q3 2022 and has held it in 15 quarters since. The position peaked at $3.98M in Q4 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Algert Global held 34,778 shares of Castle Biosciences worth $854K as of Q1 2026.
  • Algert Global bought 15,800 Castle Biosciences shares in Q1 2026, an estimated $517K.
  • Castle Biosciences made up 0.01% of Algert Global's portfolio in Q1 2026, its #893 holding.
  • Algert Global first reported a position in Castle Biosciences in Q3 2022 and has held it in 15 quarters since.
  • Algert Global's Castle Biosciences position peaked at $3.98M in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.